biostudies-literatureUnknown28(46)Anderle K<h4>Background</h4>Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder with poor response to treatment. IBS with predominant diarrhea (IBS-D) is accompanied by abdominal pain as well as high stool frequency and urgency. Purified clinoptilolite-tuff (PCT), which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR^®, has previously shown therapeutic potential in other indications based on its physical adsorption capacity.<h4>Aim</h4>To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.<h4>Methods</h4>In this randomized, placebo-controlled, double-blind pilot study, 30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled. Following a 4-wk run-in phase, 14 paWorld journal of gastroenterology6573-6588https://www.ebi.ac.uk/biostudies/studies/S-EPMC9782844biostudies-literatureSafety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.PMC9782844Gouya GWolzt MMoser GPeter JFreissmuth MTschegg CMeisslitzer CAnderle KKeip BfalseSafety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.<h4>Background</h4>Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder with poor response to treatment. IBS with predominant diarrhea (IBS-D) is accompanied by abdominal pain as well as high stool frequency and urgency. Purified clinoptilolite-tuff (PCT), which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR^®, has previously shown therapeutic potential in other indications based on its physical adsorption capacity.<h4>Aim</h4>To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.<h4>Methods</h4>In this randomized, placebo-controlled, double-blind pilot study, 30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled. Following a 4-wk run-in phase, 14 pa2022-01-01T00:00:00Z2022 Dec2025-04-21T14:10:43.655Z2025-02-19T03:01:33.957ZS-EPMC97828443656927710.3748/wjg.v28.i46.6573